Skip to main content

Table 4 Sleep actigraphy data

From: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study

 

PEA

Placebo

Baseline

Week 4

Week 8

Baseline

Week 4

Week 8

Total Sleep time (hrs)

7.49 ± 1.1

7.66 ± 1.2

7.58 ± 1.1

7.52 ± 1.2

7.54 ± 1.2

7.48 ± 1.1

Sleep Time (hrs)

7.00 ± 1.0

7.10 ± 1.0

7.03 ± 1.1

6.98 ± 1.2

7.02 ± 1.2

6.97 ± 1.1

Interruptions (min)

34.3 ± 14.1

32.3 ± 11.6

32.2 ± 11.2

32.1 ± 12.2

31.3 ± 12.4

30.9 ± 11.8

Sleep quality (1–5)

2.7 ± 0.6

3.1 ± 0.7

3.1 ± 0.7

2.5 ± 0.7

3.0 ± 0.7

2.9 ± 0.9

Sleep Continuity (1–5)

3.2 ± 0.9

3.2 ± 0.9

3.2 ± 0.9

3.2 ± 0.9

3.4 ± 1.0

3.3 ± 0.9

Sleep Percentage (%)

92.4 ± 3.9

92.9 ± 3.0

92.8 ± 2.4

92.8 ± 3.0

91.1 ± 7.5

93.0 ± 2.9

  1. N.B. Data presented as mean ± standard deviation; total sleep time = sleep time + interruptions + sleep latency; PEA palmitoylethanolamide